Monopar Therapeutics
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedule
1. Financial Statements
INDEX TO FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 207) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2023 and 2022 | F-4 |
| Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2023 and 2022 | F-5 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022 | F-6 |
| Notes to Consolidated Financial Statements | F-7 to F-22 |
2. Financial Statements Schedules
Other financial statements schedules are not included because they are not required, or the information is otherwise shown in the Consolidated Financial Statements or notes thereto.
(b) Exhibits
The following exhibits are filed as part of this Annual Report on Form 10-K.
| Exhibit | Document | Incorporated by Reference From: |
| 3.2 | Amended and Restated Bylaws | Form 10-Q filed on May 12, 2022 |
| 4.1 | Description of Registered Securities | Filed herewith as Exhibit 4.1 |
| 10.2* | Contribution Agreement (351) – Containing Registration Rights with TacticGem | Form 10-K filed on March 26, 2018 |
| 10.3 | 2016 Stock Incentive Plan, as amended | Form DEF14A filed on April 29, 2022 |
| 10.7 | Employment Agreement of Chandler D. Robinson – effective November 1, 2017 | Form 10-K filed on March 26, 2018 |
| 10.8 | Employment Agreement of Kim R. Tsuchimoto – effective November 1, 2017 | Form 10-K filed on March 26, 2018 |
| 10.9 | Amendment One to Employment Agreement of Kim R. Tsuchimoto – effective March 1, 2018 | Form 10-K filed on March 26, 2018 |
| 10.10 | Consulting Agreement of pRx Consulting (Patrice Rioux) – effective January 1, 2023 | Filed herewith as Exhibit 10.1 |
| 10.11 | Consulting Agreement of Christopher M. Starr – effective January 1, 2022 | Form 10-K filed on March 24, 2022 |
| 10.12 | Capital on DemandTM Sales Agreement with JonesTrading Institutional Services, LLC | Form 8-K filed on April 20, 2022 |
| 21.1 | Subsidiaries of Monopar Therapeutics Inc. as of December 31, 2023 | Filed herewith as Exhibit 21.1 |
| 23.1 | Consent of Independent Registered Public Accounting Firm | Filed herewith as Exhibit 23.1 |
| 24.1 | Power of Attorney (included in the signature page hereto) | |
| 31.1 | Certification of Chandler D. Robinson, Chief Executive Officer | Filed herewith as Exhibit 31.1 |
| 31.2 | Certification of Kim R. Tsuchimoto, Chief Financial Officer | Filed herewith as Exhibit 31.2 |
| 32.1 | Certification of Chandler D. Robinson, Chief Executive Officer and Kim R. Tsuchimoto, Chief Financial Officer | Filed herewith as Exhibit 32.1 |
| 97 | Compensation Recoupment Policy | Filed herewith as Exhibit 97 |
| 101.INS | Inline XBRL Taxonomy Extension Schema |
| 101.SCH | Inline XBRL Taxonomy Extension Schema |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |
Confidential Information has been omitted and filed separately with the SEC on exhibits marked with (*). Confidential treatment has been approved with respect to the omitted information, pursuant to an Order dated January 8, 2018.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MONOPAR THERAPEUTICS INC | ||
| Dated: March 28, 2024 | By: | /s/ Kim R. Tsuchimoto |
|---|---|---|
| Name: Kim Tsuchimoto | ||
| Title: Chief Financial Officer | ||
| (Principal Financial Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.